BPC-157
A synthetic pentadecapeptide derived from a fragment of human gastric juice protein BPC. Reportedly investigated for connective tissue repair, gut healing, and neuroprotection; typically sold for self-administered injection or oral capsule use. Most evidence is rodent-model preclinical; human trials are sparse, and its compounding eligibility was revoked in the US in 2026.
Side effects & risks
BPC-157 has not been evaluated in large-scale, randomised controlled trials in humans. Accordingly, no comprehensive human safety profile exists. The risk profile is, in practical terms, unknown.
In the published animal studies — predominantly rodent models — no significant toxicity was reported at the doses studied. Sikiric et al. (1997, 2018) documented no lethal dose in acute rodent toxicity testing. However, the absence of observed toxicity in rodent models is not equivalent to demonstrated human safety; the extrapolation cannot be made without human trial data.
Community reports describe a range of subjective adverse experiences, including nausea (most commonly reported), mild dizziness, and temporary changes in sleep quality. The frequency and causality of these reports cannot be assessed without controlled data. Drug interactions have not been studied systematically; any concomitant use of anticoagulants, NSAIDs, or other compounds with tissue-remodelling effects warrants clinical judgment.
BPC-157 is not approved for human therapeutic use in any major regulatory jurisdiction. Individuals obtaining it as a research chemical assume an undetermined risk profile.
Evidence summary
Latest studies
Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis.
Researchers engineered a bacterium, Bacillus licheniformis, to manufacture BPC 157 attached to a larger carrier protein, then tuned the fermentation recipe until output roughly tripled. They gave the purified fusion proteins to rats with alcohol-induced stomach ulcers and measured ulcer area and inflammatory signals. Ulcer damage was 75 to 85 percent lower than in control animals, and three inflammatory markers fell in stomach tissue. All of the work was done in bacteria and rats.
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
This narrative review gathers what is currently known about several regenerative peptides — BPC-157, thymosin beta-4/TB-500, GHK-Cu and related compounds — in the context of long-term pain management and tissue repair. The authors describe proposed mechanisms and safety profiles, then conclude that human clinical evidence is still thin. Most of these compounds are not FDA-approved for these uses.
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
Researchers systematically searched the published literature on six peptides marketed for injury recovery and athletic performance - BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu - and found that about two-thirds of the studies were preclinical, mostly in rats. The handful of human studies were small, often lacked robust control groups, and showed at best modest changes in metabolic bone health measures and degenerative knee pain. The authors also flag documented risks, including congestive heart failure with MK-677 and insulin resistance, and conclude the marketing claims are not yet substantiated by human trials.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“How local is the Wolverine Stack (BPC-157 + TB-500)”
A question thread about the so-called Wolverine Stack of BPC-157 and TB-500, asking whether injecting near an injury produces a localized effect or whether the peptides act systemically regardless of injection site.
“BPC-157 vs TB-500 (and where KPV fits): what the published record actually says”
A comparison thread reviewing what published research says about BPC-157 and TB-500, and where the smaller peptide KPV fits within that evidence landscape.
“BPC-157 vs TB-500 (and where KPV fits): what the published record actually says”
A comparison thread walking through the published record on BPC-157 versus TB-500 and situating KPV alongside them, with emphasis on what the evidence does and does not show.
“IGH 1-LR3, glutathione, CJC-1295 IPAMORELIN, klow stack”
A multi-compound stack thread covering IGF-1 LR3, glutathione, the CJC-1295 plus Ipamorelin combo, and the KLOW blend (KPV, GHK-Cu, BPC-157, TB-500), likely asking how to sequence or dose the full protocol.
“BPC-157 vs TB-500? Why do people call this the Wolverine combo?”
A discussion asking why BPC-157 and TB-500 are commonly stacked and referred to as the 'Wolverine combo' in recovery-focused communities, inviting comparison of the two compounds and the rationale users give for combining them.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Tissue repair (general) | SC or IM injection | 200–500 mcg/day total (single or divided) | Once daily (some reports divide the dose) | 4–12 weeks |
| GI support | Oral (bioavailability unstudied in humans) | Not established | Reported variable | Reported variable |
Frequently asked questions
- What are the known risks and side effects of BPC-157?
- No comprehensive human safety data has been published. In animal studies, acute toxicity was not observed at the doses studied. Community reports describe nausea, dizziness, and sleep changes, but these have not been assessed in controlled trials. Drug interactions are unstudied. The risk profile for human use is, in practical terms, unknown.
- How strong is the evidence for BPC-157?
- The evidence is emerging-to-preclinical. Multiple rodent studies — predominantly from one research group (Sikiric et al., University of Zagreb) — have associated BPC-157 with tissue repair and GI healing endpoints. Independent replication from other groups is limited. No large-scale randomised controlled trial in humans has been published as of mid-2026. The lead researcher holds patents on BPC-157 and has reported commercial interests in the compound, which is a material consideration when evaluating the body of evidence.
- Is BPC-157 legal to buy or use?
- BPC-157 is not approved for human therapeutic use in the United States, Australia, Canada, the UK, or most of the EU. The FDA removed BPC-157 from its Category 2 compounding list (~April 2026), meaning it can no longer be legally compounded by 503A/503B pharmacies in the US. In most jurisdictions it is sold as a research chemical. Regulatory status varies by country and is subject to change; verify current status with a qualified legal or clinical professional.
- What is BPC-157 believed to do in the body?
- Researchers hypothesize that BPC-157 modulates the nitric oxide system, growth hormone receptor expression, and VEGF pathways, based on animal and cell-culture studies. These mechanisms have not been confirmed in human clinical pharmacology studies. The mechanistic picture is incomplete.
- Are there human clinical trials for BPC-157?
- No large-scale, peer-reviewed, placebo-controlled human trials have been published as of mid-2026. A small number of open-label pilot reports and conference proceedings exist, but they do not constitute clinical trial evidence by standard methodology criteria.
- Is there a conflict of interest in BPC-157 research?
- A substantial majority of the published BPC-157 preclinical research originates from the laboratory of Predrag Sikiric at the University of Zagreb. Sikiric holds patents on BPC-157 and has been reported to have a commercial stake in the compound (per medical journalism coverage including STAT News and Undark, 2026). Readers should weigh this concentration of evidence from a single COI-affected research group when evaluating the strength of the preclinical literature. Independent replication by researchers without financial interests in the compound is a recognized gap in the evidence base.